GLP-3 RT

GLP-3 RT is supplied as a retatrutide-class research peptide: a single 39-amino-acid sequence that simultaneously agonizes the GLP-1, GIP, and glucagon receptors. The "RT" suffix references the retatrutide (LY3437943) scaffold first described by Coskun et al. (Cell Metabolism, 2022). Material is for in vitro research use only and is not a drug.

A single peptide ligand activates three distinct Class B G-protein-coupled receptors: GLP-1R, GIPR, and GcgR. Reported in vitro potencies relative to endogenous hormones are roughly 0.4x at GLP-1R, 8.9x at GIPR, and 0.3x at GcgR (Coskun et al. 2022). Glucagon-receptor recruitment adds an energy-expenditure axis on top of incretin-mediated satiety and insulinotropic signaling.

The reference scaffold is a 39-residue peptide (~4731 Da) built on a GIP backbone, with 2-aminoisobutyric acid (Aib) at positions 2 and 20 to confer DPP-4 resistance, alpha-methyl-leucine at position 13, and a C20 fatty diacid moiety attached at Lys17 via a gammaGlu-AEEA spacer. The fatty acyl tail drives albumin binding for extended pharmacokinetic exposure.

Published clinical-trial datasets for the retatrutide reference compound report dose-dependent reductions in body weight (~24.2% at 48 weeks, 12 mg arm; Jastreboff et al. NEJM 2023), HbA1c (~2.2 percentage points at 24 weeks in T2D subjects; Rosenstock et al. Lancet 2023), and intrahepatic fat (~86% in MASLD subjects; Sanyal et al. Nature Medicine 2024).

Typical in vitro and preclinical uses include: cell-based GLP-1R / GIPR / GcgR potency and signaling-bias assays (cAMP, beta-arrestin); diet-induced obese (DIO) and db/db rodent models for body composition and glycemic endpoints; and comparative pharmacology studies versus tirzepatide-class dual agonists and GLP-1 mono-agonists.

Lyophilized material should be stored at -20°C for long-term stability. Once reconstituted in bacteriostatic water, store at 2-8°C and use within 14 days. Avoid repeated freeze-thaw cycles and protect from light.